Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study.
Clin Immunol
; 239: 109028, 2022 06.
Article
in En
| MEDLINE
| ID: mdl-35513304
ABSTRACT
BACKGROUND:
In the absence of clinical trials evidence, Juvenile-onset Systemic Lupus Erythematosus (JSLE) treatment plans vary.AIM:
To explore 'real world' treatment utilising longitudinal UK JSLE Cohort Study data.METHODS:
Data collected between 07/2009-05/2020 was used to explore the choice/sequence of immunomodulating drugs from diagnosis. Multivariate logistic regression determined how organ-domain involvement (pBILAG-2004) impacted treatment choice.RESULT:
349 patients met inclusion criteria, median follow-up 4-years (IQR2,6). Mycophenolate mofetil (MMF) was most commonly used for the majority of organ-domains, and significantly associated with renal involvement (OR1.99, 95% CI1.65-2.41, pc < 0.01). Analyses assessing the sequence of immunomodulators focused on 197/349 patients (meeting relevant inclusion/exclusion criteria). 10/197 (5%) solely recieved hydroxychloroquine/prednisolone, 62/197 (31%) received a single-immunomodulator, 69/197 (36%) received two, and 36/197 patients (28%) received ≥three immunomodulators. The most common first and second line immunomodulator was MMF. Rituximab was the most common third-line immunomodulator.CONCLUSIONS:
Most UK JSLE patients required ≥two immunomodulators, with MMF used most commonly.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Lupus Erythematosus, Systemic
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Year:
2022
Type:
Article